JP2008513379A5 - - Google Patents

Download PDF

Info

Publication number
JP2008513379A5
JP2008513379A5 JP2007531552A JP2007531552A JP2008513379A5 JP 2008513379 A5 JP2008513379 A5 JP 2008513379A5 JP 2007531552 A JP2007531552 A JP 2007531552A JP 2007531552 A JP2007531552 A JP 2007531552A JP 2008513379 A5 JP2008513379 A5 JP 2008513379A5
Authority
JP
Japan
Prior art keywords
hmg
coa reductase
reductase inhibitor
polychitosamine
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007531552A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008513379A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2005/001406 external-priority patent/WO2006029524A1/en
Publication of JP2008513379A publication Critical patent/JP2008513379A/ja
Publication of JP2008513379A5 publication Critical patent/JP2008513379A5/ja
Pending legal-status Critical Current

Links

JP2007531552A 2004-09-15 2005-09-14 高脂血症のためのポリキトサミンとＨＭＧ−ＣｏＡレダクターゼ阻害剤との組み合わせ Pending JP2008513379A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60983004P 2004-09-15 2004-09-15
PCT/CA2005/001406 WO2006029524A1 (en) 2004-09-15 2005-09-14 Combination of polychitosamine and hmg-coa reductase inhibitor for hyperlipidemia

Publications (2)

Publication Number Publication Date
JP2008513379A JP2008513379A (ja) 2008-05-01
JP2008513379A5 true JP2008513379A5 (https=) 2008-09-18

Family

ID=36059676

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007531552A Pending JP2008513379A (ja) 2004-09-15 2005-09-14 高脂血症のためのポリキトサミンとＨＭＧ−ＣｏＡレダクターゼ阻害剤との組み合わせ

Country Status (8)

Country Link
US (5) US20060058261A1 (https=)
EP (1) EP1812019A4 (https=)
JP (1) JP2008513379A (https=)
CN (1) CN101052405A (https=)
AU (1) AU2005284565A1 (https=)
BR (1) BRPI0515443A (https=)
CA (1) CA2580460A1 (https=)
WO (1) WO2006029524A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20080182819A1 (en) * 2007-01-29 2008-07-31 Act Iii Licensing, Llc Chitosan compositions and methods for using chitosan compositions in the treatment of health disorders
KR101913109B1 (ko) 2009-03-18 2018-10-31 리스버로직스 코퍼레이션 신규한 소염제
CN102625705B (zh) 2009-04-08 2015-05-06 南洋理工学院 包含他汀类药物的植物提取物及其制备技术和用途
WO2012171125A1 (en) 2011-06-13 2012-12-20 Rival, Société En Commandite N,n,n-trialkylpolymers, methods of their preparation and uses thereof
JP7437392B2 (ja) * 2018-09-26 2024-02-22 テークー－ジステームス ゲーエムベーハー 電動アシスト自転車の一連の動的制御方法及び装置、電動アシスト自転車
IT201900021291A1 (it) * 2019-11-15 2021-05-15 Biomedica Pharma Gmbh Chitosano e prodotto medicale per l’uso in un metodo di prevenzione o trattamento di una malattia cardiovascolare

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3903140A (en) * 1970-09-08 1975-09-02 Alza Corp Diazadodecane prostaglandin compounds
US4231938A (en) * 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4444784A (en) * 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
DK149080C (da) * 1980-06-06 1986-07-28 Sankyo Co Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre
US4739073A (en) * 1983-11-04 1988-04-19 Sandoz Pharmaceuticals Corp. Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof
JP3863913B2 (ja) * 1992-12-01 2006-12-27 スリーエム カンパニー 永続性抗菌剤
FI107432B (fi) * 1997-02-06 2001-08-15 Novasso Oy Mikrokiteisen kitosaanin käyttö
FI982291L (fi) * 1998-10-23 2000-04-24 Novasso Oy Aine kolesterolin sekä lipidien pitoisuuden alentamiseksi
US20020016307A1 (en) * 1999-10-27 2002-02-07 Mullins John Jason Gentry Pharmaceutical composition with both a lipase inhibitor and a lipophilic polysaccharide and an improved method for treating adiposity
US6933291B2 (en) * 2000-12-01 2005-08-23 N.V. Nutricia Cholesterol lowering supplement
KR20040026705A (ko) * 2001-08-16 2004-03-31 테바 파마슈티컬 인더스트리즈 리미티드 스타틴의 칼슘 염 형태의 제조 방법
GB0302738D0 (en) * 2003-02-06 2003-03-12 Advanced Biopolymers As Composition

Similar Documents

Publication Publication Date Title
Quirk et al. Rosuvastatin calcium
FI3911648T3 (fi) 6'-[[[(1s,3s)-3-[[5-(difluorometoksi)-2-pyrimidinyyli]amino]syklopentyyli]amino][1(2h),3'-bipyridin]-2-oni pcsk9:n estäjänä ja menetelmät sen käyttöön
Corsini et al. New insights into the pharmacodynamic and pharmacokinetic properties of statins
RU2007126483A (ru) Гетероциклические ингибиторы аспартилпротеазы
JP2022116083A5 (https=)
RU2022100434A (ru) Фармацевтические композиции, содержащие epa и сердечно-сосудистое средство, и способы их применения
JP2010047616A5 (https=)
JP2002501887A5 (ja) アルツハイマー病の治療用の薬剤の製造のための血漿トリグリセライドレベル低下剤の使用
JP2015503588A5 (https=)
FI3666797T3 (fi) Antigeeniä sitovia proteiineja tyypin 9 proproteiinikonvertaasi-subtilisiini-keksiinille (pcsk9)
JP2016518338A5 (https=)
RU2006102356A (ru) Лечение и предотвращение сердечно-сосудистых заболеваний
JP2015524439A5 (https=)
JP2018508551A5 (ja) 心血管疾患を処置するか又は心血管疾患のリスクを低減させるためのｅｔｃ１００２及び１種以上のスタチンを含む固定用量組合せ物
JP2008513379A5 (https=)
JP2002525321A5 (ja) カテーテルによる血管再生を予防または遅らせる医薬組成物の製造のためのコレステロール低下剤の使用
Paraskevas et al. Pleiotropic effects of statins: implications for a wide range of diseases
JP2013536408A5 (https=)
JP2007530528A5 (https=)
CA2529367A1 (en) Preventing atrial fibrillation (af) with the use of statin drugs
JP2007534731A5 (https=)
WO2005058310A3 (en) Use of stating for the treatment of metabolic syndrome
RU2007148908A (ru) Составы для снижения риска возникновения вызванной лекарственными средствами аритмии
JP2005525391A5 (https=)
RU2006114579A (ru) Комбинации ингибитора биосинтеза холестерина и растворимого волокна для лечения состояний, связанных с повышенным содержанием холестерина